NCT00733187已完成1 期
A Pharmacokinetic Study to Evaluate the Effect of Food on the Oral Bioavailability and Effect of Diurnal Variation on the Pharmacokinetics of ABT-869
AbbVie (prior sponsor, Abbott)0 个研究点目标入组 34 人开始时间: 2009年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 34
- 主要终点
- Pharmacokinetic
研究概览
简要总结
To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.
详细描述
This study is a pharmacokinetic study designed to evaluate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869. Triplicate ECG performed to determine the effect of ABT-869 on QT prolongation . Subjects may continue receiving linifanib after completion of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female and age is ≥ 18 years.
- •Must have a histologically or cytologically confirmed non-hematologic malignancy that is refractory to standard therapies or for which a standard effective therapy does not exist.
- •Has measurable or evaluable disease.
- •Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-
- •Must have adequate bone marrow, renal and hepatic function as follows:
- •Bone Marrow: Absolute neutrophil count (ANC) ≥ 1,500/mm³; Platelets ≥ 100,000/mm³; Hemoglobin ≥ 9.0 g/dL (1.4 mmol/L)
- •Renal function: serum creatinine ≤ 2.0 mg/dL (0.81 mmol/L);
- •Hepatic function: AST and ALT ≤ 1.5 × ULN unless liver metastases are present, then AST and ALT ≤ 5.0 × ULN; bilirubin ≤ 1.5 mg/dL (0.026 mmol/L)
- •Must have PTT ≤ 1.5 × ULN and/or INR ≤ 1.5 .
- •Women of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and up to two months following completion of therapy. Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment and/or post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •total abstinence from sexual intercourse (minimum one complete menstrual cycle);
- •a vasectomized partner;
- •hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration;
- •intrauterine device; * double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream)
- •Is capable of understanding and complying with parameters as outlined in the protocol and able to sign the informed consent.
- •Must voluntarily sign and date each informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
排除标准
- •Has received anti-cancer therapy within 21 days or within a period defined by 5 half lives, whichever is shorter, prior to study drug administration. Has not recovered to less than or equal to Grade 1 clinically significant adverse effects/toxicities of the previous therapy. Avastin must not have been used less than 60 days prior to receiving ABT-
- •Has had major surgery within 21 days of Study Day
- •Has untreated brain or meningeal metastases. Subjects with treated, stable, asymptomatic central nervous system lesions may be considered. Subject must have had stable disease for at least 4 weeks prior to study entry.
- •Has been diagnosed with hepatocellular carcinoma.
- •Pregnant or breastfeeding female.
- •Is receiving therapeutic anticoagulation therapy. Low dose anticoagulation for catheter prophylaxis will be permitted.
- •Has a history of/or currently exhibits clinically significant cancer related events of bleeding. The subject has a recent history of (within 4 weeks of Study Day 1) or currently exhibits other clinically significant signs of bleeding.
- •Has proteinuria CTC Grade > 1 at baseline as measured by a UPC ratio of > 1 and confirmed by a 24 hour urine collection. . Currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (BP) > 100 mmHg; or systolic blood pressure (BP) > 150 mmHg.
- •Has a history of myocardial infarction within 6 months of Study Day
- •Has known autoimmune disease with renal involvement.
- •Is receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV).
- •Clinically significant uncontrolled condition(s).
- •Has active ulcerative colitis, Crohn's disease or celiac disease.
- •LV Ejection Fraction < 50%.
- •Current or previous enrollment in another clinical study.
研究组 & 干预措施
1
Experimental
干预措施: ABT-869 (Drug)
结局指标
主要结局
Pharmacokinetic
时间窗: Various timepoints
Blood samples for the pharmacokinetics of linifanib will be collected for each subject and each regimen (fasting, fed, AM and PM dosings).
ECG Evaluation
时间窗: Various timepoints
Triplicate ECG will be performed at designated timepoints.
Adverse Events
时间窗: Throught the study
Only treatment emergent AEs will be included. Toxicity grade, relationship to study drug and AEs leading to discontinuation will be evaluated.
Lab data and vital signs
时间窗: Various timepoints
Blood chemistry and hematology will be analyzed based on the regimen and dosing and overall. 24 hr ABPM will be analyzed by regimen and dosing time and overall.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male VolunteersHealthyNCT02172209Boehringer Ingelheim14
已完成
1 期
A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941HealthyPharmacokinetics of ASP1941NCT01674777Astellas Pharma Inc30
已完成
1 期
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With MethotrexateInflammationNCT03244462Bayer10
已完成
1 期
Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsHealthy Adult SubjectsNCT05002231Fulcrum Therapeutics18
已完成
1 期
Comparative Bioavailability Study of BIA 9-1067 25 mg CapsulesParkinsonNCT02071823Bial - Portela C S.A.12